Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study (Q40340899)
Jump to navigation
Jump to search
scientific article published on December 13, 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study |
scientific article published on December 13, 2010 |
Statements
1 reference
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study (English)
1 reference
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The HERNATA Study (English)
1 reference
Per Karlsson
Michael Andersson
1 reference
Elisabeth Lidbrink
1 reference
Karsten Bjerre
1 reference
Erik Wist
1 reference
Kristin Enevoldsen
1 reference
Susanne Møller
1 reference
Anders B. Jensen
Ulla B. Tange
Peter G. Sørensen
Sven T. Langkjer
13 December 2010
1 reference
1 reference
29
1 reference
3
1 reference
264-271
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference